Literature DB >> 21564440

Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients - a systematic review and meta-analysis.

G Trikudanathan1, J Israel, J Cappa, D M O'Sullivan.   

Abstract

Acid suppressive therapy, in the form of proton pump inhibitor (PPI), is widely used in cirrhotic patients, often in indications which are not clearly justified. PPI facilitates enteric bacterial colonisation, overgrowth and translocation, which might predispose to spontaneous bacterial peritonitis. However, observational studies evaluating the association of PPI and SBP in cirrhotic patients have yielded inconsistent results. We therefore conducted a meta-analysis of relevant clinical studies to determine the nature of this association. Observational studies assessing the association between SBP and PPI in cirrhosis, conducted in adult population and published in all languages, were identified through systematic search in the MEDLINE, EMBASE and manual reviews of all major gastroenterology meeting proceedings up to May 2010. The relevant studies were pooled using traditional meta-analytic techniques with a random-effects model. Four studies were identified and included in the meta-analysis. The pooled analysis, involving a total of 772 patients, found a significant association between the use of PPI and the development of SBP (OR 2.77, 95% CI 1.82-4.23). There was very little degree of heterogeneity as reflected by an I(2) value of 22% and the visual inspection of the funnel plot. There is a potential association between use of PPI and development of SBP. Therefore, PPIs should be used judiciously and only when clearly indicated in cirrhotics. Further studies are essential to clarify this relationship and elucidate the underlying mechanisms.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21564440     DOI: 10.1111/j.1742-1241.2011.02650.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  36 in total

1.  Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos
Journal:  World J Hepatol       Date:  2015-08-18

Review 2.  Potential harms of proton pump inhibitor therapy: rare adverse effects of commonly used drugs.

Authors:  Amine Benmassaoud; Emily G McDonald; Todd C Lee
Journal:  CMAJ       Date:  2015-11-23       Impact factor: 8.262

Review 3.  Bacterial Infection in Patients with Cirrhosis: Don't Get Bugged to Death.

Authors:  Mary D Cannon; Paul Martin; Andres F Carrion
Journal:  Dig Dis Sci       Date:  2020-01       Impact factor: 3.199

Review 4.  Multi-resistant bacteria in spontaneous bacterial peritonitis: a new step in management?

Authors:  Angelo Alves de Mattos; Ane Micheli Costabeber; Livia Caprara Lionço; Cristiane Valle Tovo
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

5.  The burden of extended-spectrum β-lactamase-producing Enterobacteriaceae in patients with cirrhosis.

Authors:  Richard Moreau
Journal:  Hepatol Int       Date:  2014-09-06       Impact factor: 6.047

Review 6.  Optimizing medication management for patients with cirrhosis: Evidence-based strategies and their outcomes.

Authors:  Mary J Thomson; Anna S Lok; Elliot B Tapper
Journal:  Liver Int       Date:  2018-06-19       Impact factor: 5.828

Review 7.  Emergent Transjugular Intrahepatic Portosystemic Shunt Creation in Acute Variceal Bleeding.

Authors:  Mithil B Pandhi; Andrew J Kuei; Andrew J Lipnik; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2020-03-04       Impact factor: 1.513

8.  Diagnosis and management of bacterial infections in decompensated cirrhosis.

Authors:  Maria Pleguezuelo; Jose Manuel Benitez; Juan Jurado; Jose Luis Montero; Manuel De la Mata
Journal:  World J Hepatol       Date:  2013-01-27

9.  Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations.

Authors:  Carmen C Franz; Carole Hildbrand; Christa Born; Sabin Egger; Alexandra E Rätz Bravo; Stephan Krähenbühl
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

10.  Proton Pump Inhibitor Therapy Increases the Risk of Spontaneous Bacterial Peritonitis in Patients with HBV-Related Acute-on-Chronic Liver Failure.

Authors:  Meng Zhang; Xin Xu; Wei Liu; Zhongwei Zhang; Qiuyu Cheng; Zhongyuan Yang; Tingting Liu; Yunhui Liu; Qin Ning; Tao Chen; Junying Qi
Journal:  Adv Ther       Date:  2021-07-25       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.